Invokana (Canagliflozin) Litigation
Overview of Invokana as a Diabetes Treatment
Invokana (Canagliflozin) belongs to the gliflozin class of drugs, specifically categorized as a subtype 2 sodium-glucose transport inhibitor (SGLT-2). It is prescribed for the treatment of type 2 diabetes mellitus and is designed to help lower blood sugar levels in patients. Manufactured and sold by Janssen Pharmaceuticals, Inc., along with its associated and affiliated companies, Invokana has been a significant medical intervention for type 2 diabetics.
Health Risks Associated with Invokana
Recent findings have revealed that Invokana usage can lead to several severe health complications. These include diabetic ketoacidosis/ketosis, kidney failure, and cardiovascular events such as myocardial infarctions. Diabetic ketoacidosis (DKA), a specific form of acidosis occurring in diabetic patients, presents with symptoms like nausea, vomiting, and abdominal pain and can escalate to more severe conditions, including cerebral edema, coma, and potentially death.
Legal Focus on Invokana’s Side Effects
The discovery of these health risks has led to increased scrutiny and legal challenges. The Levensten Law Firm is actively involved in Invokana litigation, representing individuals who have suffered from these severe side effects.
Contacting The Levensten Law Firm for Invokana Claims If you or someone you know has experienced adverse health effects from Invokana, The Levensten Law Firm offers free consultations to discuss potential legal claims. Our firm is committed to helping affected individuals understand their rights and seek appropriate compensation.